

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

200003929-7. IPOB.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 275/42, 237/22, A61K 31/17, 31/16	A1	(11) International Publication Number: WO 99/37605
		(43) International Publication Date: 29 July 1999 (29.07.99)

(21) International Application Number: PCT/EP99/00384

(22) International Filing Date: 21 January 1999 (21.01.99)

(30) Priority Data:

① 09/012,336 /	23 January 1998 (23.01.98) /	US /
② 60/110,723 /	3 December 1998 (03.12.98) /	US /

(71) Applicant (for all designated States except AT US): NOVARTIS AG (CH/CH); Schwarzwaldallee 215, CH-4058 Basel (CH).

(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1235 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ① WATTANASIN, Sompong, [TH/US]; 11 Divito Trail, Hopatcong, NJ 07843 (US).

② VON MATT, Peter, Josef, [CH/US]; 37 Wetmore Avenue, Morristown, NJ 07960 (US).

(74) Agent: BECKER, Konrad; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published

With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

2 PDs.
1 Applⁿ.
2 Invs. (2nd Inv's address)
pls see IB/306

(54) Title: VLA-4 ANTAGONISTS

IPC : C07C 275/42
IPER 17/7/99



(57) Abstract

Compounds of formula (I) and their pharmaceutically acceptable salts are VLA-4 antagonists. They are useful in inhibiting cell adhesion and in the therapeutic or prophylactic treatment of inflammatory and autoimmune diseases, particularly inflammatory airways diseases. They are particularly useful in reducing post-surgical inflammation, especially that resulting from transplant surgery.